Picture of Intervacc AB logo

IVACC Intervacc AB Share Price

0.000.00%
se flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapSucker Stock

Momentum

Relative Strength (%)
1m+19.05%
3m-32.69%
6m-36.49%
1yr-40.81%
Volume Change (%)
10d/3m-54.27%
Price vs... (%)
52w High-60.42%
50d MA+2.71%
200d MA-18.9%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-39.31%
Return on Equity-42.14%
Operating Margin-1167.55%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202431st Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Intervacc AB EPS forecast chart

Profile Summary

Intervacc AB is a Sweden-based biotechnology company. It develops vaccines based on recombinant proteins for animal health care. The Company’s candidate vaccine against strangles Strangvac consists of soluble recombinant proteins and devoids any living infectious agent. The Company operates through two subsidiaries: Nord Vacc Lakemedel AB and Mybac-Vettech AB. Nord Vacc Lakemedel AB markets and distributes veterinary vaccines, pharmaceuticals and vitamins on European market. It offers assortment of fur animal vaccines, the Febrivac range, as well as swine vaccines for Swedish and Danish markets. Mybac-Vettech AB is a technology platform that focuses on diagnostics in the Swedish animal health market and offers bacteriological and mycological analyses.

Directors

Last Annual
December 31st, 2023
Last Interim
December 31st, 2023
Incorporated
December 22nd, 1983
Public Since
April 7th, 2017
No. of Shareholders
17,000
No. of Employees
15
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
se flag iconOMX Nordic Exchange Stockholm
Shares in Issue
75,736,264
Blurred out image of a map
Address
Vastertorpsvagen 135, HAGERSTEN, 129 44
Web
http://intervacc.se/
Phone
+46 812010600
Auditors
Ohrlings PricewaterhouseCoopers AB

IVACC Share Price Performance

Upcoming Events for IVACC

Q1 2024 Intervacc AB Earnings Release

Intervacc AB Annual Shareholders Meeting

Intervacc AB Annual Shareholders Meeting

Q2 2024 Intervacc AB Earnings Release

Similar to IVACC

Picture of 2cureX AB logo

2cureX AB

se flag iconOMX Nordic Exchange Stockholm

Picture of Abliva AB logo

Abliva AB

se flag iconOMX Nordic Exchange Stockholm

Picture of Acousort AB logo

Acousort AB

se flag iconOMX Nordic Exchange Stockholm

Picture of Active Biotech AB publ logo

Active Biotech AB publ

se flag iconOMX Nordic Exchange Stockholm

Picture of AddLife AB logo

AddLife AB

se flag iconOMX Nordic Exchange Stockholm

FAQ